Additionally, the low-risk group glioma samples possessed more frequent mutations in IDH, ATRX and CIC genes, whose mutations possess anti-tumor effects in gliomas (Yan et al., 2009; Bettegowda et al., 2011; Qin et al., 2022). This evidence concerns the gene IDH1 and central nervous system cancer.